Our specialist medical device team work with diverse global companies within the industry to sustain growth, exploit current and future innovations, and secure their business's success. Our clients are multinational corporations and start-ups within the medical devices industry from companies within medical devices or in vitro diagnostic medical devices.
With sector-specific expertise grounded in scientific intelligence and technological know-how, clients value our knowledge of the regulatory frameworks shaping clients' strategic options, the technology being deployed, and our ability to execute complex legal solutions across multi-jurisdictions.
We ensure that our clients operate within the boundaries of medical regulations, data privacy, competition/anti-trust, procurement, pricing and reimbursement, advertising and promotion, and anti-bribery compliance/fraud and abuse laws.
We are pivotal in leveraging growth through strategic alliances, fundraisings, IP and compliant data privacy and security activities, and are relied on to resolve both offensive and defensive cross-jurisdiction patent litigation.
With in-depth sector expertise, we also actively engage with the wider medical devices industry through our connections with esteemed industry bodies and as leading voices in industry publications and wider expert webinar/seminar series.
Die börsennotierte Eckert & Ziegler Strahlen- und Medizintechnik AG, einer der weltweit größten Anbieter von isotopentechnischen Komponenten für Strahlentherapie und Nuklearmedizin mit Sitz in Berlin, hat die ebenfalls börsennotierte belgische Eckert & Ziegler BEBIG SA übernommen. Die internationale Wirtschaftskanzlei Taylor Wessing hat die Eckert & Ziegler Strahlen- und Medizintechnik AG hinsichtlich aller Aspekte der grenzüberschreitenden Verschmelzung rechtlich beraten. Die Transaktion dürfte die erste erfolgreiche Umsetzung einer grenzüberschreitenden Verschmelzung zweier börsennotierter Gesellschaften nach Deutschland auf der Grundlage der europäisch harmonisierten Vorgaben der EU-Gesellschaftsrichtlinie (EU) 2017/1132 sein.
Press release
Aktuelle News & Insights
EU and medicines supply issues (part one): Current measures
Marketing Authorisation Holders (MAHs) in the EU are legally required to report medicine supply shortages to the European Medicines Agency and national authorities. This article explores the central role of Marketing Authorisation Holders (MAHs) in identifying and managing medicine supply shortages in the EU as well as the role of EMA committees and working groups in coordinating responses and maintaining the Critical Medicines List to safeguard public health.
von Alison Dennis
2 von 5 Insights
EU and medicines supply issues (part two): Proposals for future measures
In part two of our article on EU and medicine supply issues we explore the key proposals outlined in pharmaceutical reform and their impact on marketing authorisation holders across the region.
von Alison Dennis und Alice Matthews
3 von 5 Insights
Guidance to manufacturers withdrawing a medical device from the EU market
Medical product availability and healthcare safety are becoming increasingly important talking points. This is also reflected in the EU regulations on medical devices. Although the provisions may seem straightforward their vagueness may give rise to significant doubts as to which situations they will apply to in practice.
von Bartosz Świdrak
4 von 5 Insights
Politics of France protecting the supply of critical medicines and medical devices
von Evelyne Friedel
Deutsche Regelungen zur Sicherstellung der Versorgung mit kritischen Arzneimitteln und Medizinprodukten
von mehreren Autoren